BDSX
Biodesix Inc

1,680
Mkt Cap
$146.64M
Volume
86,203.00
52W High
$20.21
52W Low
$3.44
PE Ratio
-3.14
BDSX Fundamentals
Price
$14.69
Prev Close
$14.88
Open
$14.74
50D MA
$12.58
Beta
0.47
Avg. Volume
136,529.04
EPS (Annual)
-$4.67
P/B
-49.80
Rev/Employee
$264,967.07
$105.11
Loading...
Loading...
News
all
press releases
Wall Street Analysts See an 86.45% Upside in Biodesix (BDSX): Can the Stock Really Move This High?
The mean of analysts' price targets for Biodesix (BDSX) points to an 86.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks·4d ago
News Placeholder
More News
News Placeholder
Is Biodesix (BDSX) Stock Outpacing Its Medical Peers This Year?
Here is how Biodesix, Inc. (BDSX) and Coherus Oncology (CHRS) have performed compared to their sector so far this year.
Zacks·4d ago
News Placeholder
Biodesix Details Lung Test Momentum, 81% Gross Margin and Growth Plan at Barclays Conference
Biodesix (NASDAQ:BDSX) is focused on developing diagnostic tests intended to improve patient outcomes by answering specific clinical questions, Chief Financial Officer Robin Cowie said at a Barclays...
MarketBeat·11d ago
News Placeholder
Here's Why Investors Continue to Hold Pediatrix Medical Stock
Favorable payer mix, higher neonatology acuity and prudent acquisitions will support MD's growth, while shares look undervalued versus industry peers.
Zacks·11d ago
News Placeholder
Biodesix Details Lung Nodule Growth Plan, Primary Care Push at TD Cowen Healthcare Conference
Biodesix (NASDAQ:BDSX) outlined its current commercial focus, growth priorities, and financial milestones during a presentation at the 46th annual TD Cowen Healthcare Conference, where Chief...
MarketBeat·17d ago
News Placeholder
Wall Street Analysts Think Biodesix (BDSX) Could Surge 111.62%: Read This Before Placing a Bet
The mean of analysts' price targets for Biodesix (BDSX) points to an 111.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks·20d ago
News Placeholder
Are Medical Stocks Lagging Biodesix (BDSX) This Year?
Here is how Biodesix, Inc. (BDSX) and Cabaletta Bio, Inc. (CABA) have performed compared to their sector so far this year.
Zacks·20d ago
News Placeholder
Monashee Investment Management LLC Cuts Holdings in Biodesix, Inc. $BDSX
Monashee Investment Management LLC lowered its position in Biodesix, Inc. (NASDAQ:BDSX - Free Report) by 95.0% during the third quarter, according to its most recent disclosure with the Securities...
MarketBeat·22d ago
News Placeholder
Biodesix (NASDAQ:BDSX) Announces Quarterly Earnings Results, Beats Estimates By $0.56 EPS
Biodesix (NASDAQ:BDSX - Get Free Report) released its earnings results on Thursday. The company reported ($0.49) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.05) by...
MarketBeat·24d ago
News Placeholder
GSA Capital Partners LLP Has $365,000 Stake in Biodesix, Inc. $BDSX
GSA Capital Partners LLP reduced its position in Biodesix, Inc. (NASDAQ:BDSX - Free Report) by 94.8% during the third quarter, according to the company in its most recent 13F filing with the SEC. The...
MarketBeat·24d ago
<
1
2
...
>

Latest BDSX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.